Board of Directors
Michael Demurjian
Chief Operating Officer Michael Demurjian has served as Chief Operating Officer of Tyme since its formation in July 2013
and as a cofounder and senior leader of Tyme's precursor, Luminant, since its formation in September 2011. In such roles and continuing with his position as chief
operating officer of Tyme, Mr. Demurjian leads the research teams in development, studies and data collection for submissions to
regulatory authorities, including the FDA.
Prior to the establishment of Luminant, Mr. Demurjian was a co-founder and, from 1993 to 2007,
Director of Marketing of Mikronite Technologies Group, Inc., a developer, licensor and marketer of material surfacing technologies
for various manufacturing processes and applications. At Mikronite, Mr. Demurjian established all marketing activities and functions,
marketing research and analysis, marketing strategy, implementation planning, project, process, and vendor management, organizational
management and leadership. Mr. Demurjian efforts on behalf of Mikronite were recognized by The Home Depot and Lowe’s with a Best New Product
award and an Innovative Technology award from the New Jersey Manufacturers Association. Mr. Demurjian received a BA in Economics
from New York University in 1986.
Steven Hoffman
Chief Executive Officer Steven Hoffman has served as Chief Executive Officer of Tyme since its formation in July 2013 and as
a cofounder and senior leader of Tyme's precursor, Luminant, since its formation in September 2011. In such roles and continuing with his position as Chief Executive Officer
and Chief Science Officer of Tyme, Mr. Hoffman supervises the development of our product candidates. Mr. Hoffman has over 25 years of holding
a variety of senior management positions with companies in the chemistry, aerospace and laser optics fields.
Prior to the establishment of Luminant, Mr. Hoffman was a co-founder and, from 1993 to 2007, Chief Technology Officer of Mikronite Technologies Group Inc.,
a developer, licensor and marketer of material surfacing technologies for various manufacturing processes and applications. At Mikronite, Mr. Hoffman
supervised its implementation of proprietary technology. He has received numerous patents and has pending other patent applications,
including a patent and three patent applications that have been assigned to our Company. Mr. Hoffman efforts on behalf of Mikronite were recognized
by The Home Depot and Lowe’s with a Best New Product award and an Innovative Technology award from the New Jersey Manufacturers Association.
Mr. Hoffman attended New York University and Rutgers University with a concentration in mechanical engineering from 1980 to 1984 and continued
his studies under the direct supervision of the chairman of the physics department at the University of Michigan specializing in physics and
electro-optics.
Dr. Gerald Sokol
Gerald H. Sokol MD, MSc, FCP attained his medical degree from Indiana University's Combined Degree Program in Experimental Medicine with a
Masters Degree in Pharmacology and an MD.
Dr. Sokol interned in Medicine at Temple University and attended the US Public Health Service Hospital in affiliation with the National Cancer Institute,
Johns Hopkins, and the University of Maryland completing training in Internal Medicine. He then completed training at the Massachusetts General Hospital,
Harvard Medical School in Radiation Oncology, Medical Oncology and Clinical Pharmacology attaining Board Certification in Internal Medicine, Medical Oncology, Radiation Oncology, Clinical Pharmacology, and later Quality Assurance and Utilization Review. He Is also certified in Skin Cancer Medicine from the University of Queensland.
Dr. Sokol has been Chief of Radiation Oncology at the University of South Florida's Tampa General Hospital, has built or contributed to building
over 10 highly successful cancer centers. He is a board member and partner of Florida Cancer Specialists and Research Institute
(the largest research group in Florida) consisting of over 190 physicians).
Dr Sokol is a decorated retired Captain in the US Navy and served as Commanding Officer of the unit at the Uniformed Services University.
Dr. Sokol currently holds professorships in Medicine and Pharmacology at that institution.
While maintaining a busy medical practice Dr. Sokol served on the review staff of the FDA for over 27 years as a senior regulatory
scientist and officer composing over 300 white papers, IND and NDA reviews, and opinion papers.
Dr. Sokol has authored or coauthored over 100 books, book chapter, abstracts and papers on a multitude of clinical issues. He is a
lifetime fellow and board member of the American Cancer Society and a fellow of the American College of Clinical Pharmacology.
He has a busy teaching and research schedule and enjoys spending time with grand children and family.
Tommy Thompson
Tommy G. Thompson currently is the Chairman and Chief Executive Officer of Thompson Holdings, and former United States Health and Human Services
(HHS) Secretary and four-term Governor of Wisconsin. Governor Thompson, through his work at Thompson Holdings, continues to develop innovative
solutions to the health care challenges facing American families, businesses, communities, states and the nation as a whole. These efforts
focus on improving the use of information technology in hospitals, clinics and doctors’ offices; promoting healthier lifestyles;
strengthening and modernizing Medicare and Medicaid; and expanding the use of medical diplomacy around the world.
From 2005 until 2009, Governor Thompson served as a senior advisor at the
consulting firm Deloitte LLP and was the founding independent chairman of the Deloitte Center for Health Solutions, which researches
and develops solutions to some of our nation’s most pressing health care and public health related challenges. From 2005 to early 2012,
Governor Thompson served as a senior partner at the law firm of Akin, Gump, Strauss, Hauer, & Feld LLP. Governor Thompson served as
Chairman of the Board of Directors of Logistics Health, Inc. from January 2011 to May 2011, and served as President from February 2005 to
January 2011. He currently serves on the Board of Directors of the following public companies: Physicians Realty Trust and TherapeuticsMD, Inc.,
each as Chairman of the Board of Directors, Centene Corporation, C.R. Bard, Inc., Cytori Therapeutics, Inc., TherapeuticsMD, Inc. and United
Therapeutics Corporation.
Tim Tyson
Timothy (Tim) C. Tyson is President of Alkaloida Chemical Company Zrt. Mr. Tyson served as
Interim Chief Executive Officer of Caldera Pharmaceuticals, Inc. from September 23, 2014 to November 21, 2014.
He served as Interim Chief Executive Officer and Executive Chairman of Aptuit and at Laurus Labs Private Limite since August 2008.
Mr. Tyson has over 30 years of remarkable corporate career in the pharmaceutical industry. He served as Acting Chief Executive Officer
of Aptuit LLC since September 2008. He served as the President of ICN Hungary Co., Ltd. (also called as ICN Hungary Ltd.).
Mr. Tyson served as the Chief Executive Officer of Valeant Pharmaceuticals International (formerly, ICN Pharmaceuticals Inc.)
from January 1, 2005 to February 1, 2008. He served as President of Valeant Pharmaceuticals International from November 2002 to
February 1, 2008 and served as its Chief Operating Officer from November 2002 to December 2004.
He served as President of Global Manufacturing and Supply for GlaxoSmithKline plc. from June 1998 to November 2002. From 1997 to 1998,
Mr. Tyson served as GlaxoSmithKline's Vice President and General Manager of Business Operations. During his 14-year tenure at GlaxoSmithKline,
he served in a variety of roles with broad international and domestic responsibilities, including significant management experience running
two divisions: Glaxo Dermatology and Cerenex Pharmaceuticals. He was responsible for managing all sales and marketing for the U.S. operations,
where he launched 32 new products, eight of which became blockbuster drugs.
Prior to his tenure at GlaxoSmithKline,
Mr. Tyson served in a number of executive positions at Bristol-Myers Company in Operations and Research and Development.
Prior to his tenure at Bristol-Myers, he served as a Manufacturing Manager for Procter & Gamble. He served as an Officer in the
United States Army from 1974 to 1979 and spent 14 years in the United States Army Reserves. He has been Independent Non-Executive Chairman
of Caldera Pharmaceuticals since April 1, 2014 and has been its Director since October 2013. He has been Chairman of the Board of Aptuit LLC
since August 2008 and its Manager since August 2008. He has been Independent Director of Marken Limited since March 05, 2013.
He serves as a Director of Alkaloida Chemical Company Zrt. He serves as Director of ICN Hungary Co., Ltd., and Valeant Pharmaceuticals.
He served as a Director of Ventaira Pharmaceuticals, Inc. He serves as Director for the Pharmaceutical Research and Manufacturing Association (PhRMA);
BICOM; the Chief Executive Officer Roundtable for the University of California at Irvine; the Dean's Executive Forum at Cal State Fullerton;
the Chief Executive Officer Council on Cancer; the Health Sector Advisory Board at Duke University; the Leadership Forum of the International
Society of Pharmaceutical Engineers and as a visiting lecturer at Cambridge University. Mr. Tyson serves on the board of directors for
non-profit organizations in Raleigh-Durham, NC and Orange County, CA and with the United Way. He served as a Director of Valeant Pharmaceuticals
International from 2004 to February 1, 2008. In 2002, Mr. Tyson received a Bicentennial Leadership Award from the United States Military
Academy at West Point and was named 2007 Alumnus of the Year at Jacksonville State University. Mr. Tyson received a Master in Business
Administration and Master in Public Administration from Jacksonville State University in 1979 and 1976, respectively. He is also a 1974 graduate
of the United States Military Academy at West Point.